Efficacy Study Evaluating Chemotherapy in Prostate Cancer (SensiCab)
Randomized Phase III Trial Comparing Cabazitaxel Combination Hormone Therapy to Hormone Therapy Alone in Metastatic Prostate Cancer or High Risk Disease
This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, 3) the availability of chemotherapy such as cabazitaxel that can improve survival in subjects with advanced disease and 4) that chemotherapy (docetaxel) given concomitant with hormone treatment has proven to prolong time to progression.
It is the investigators hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment.
This trial will determine whether any benefit is gained by adding chemotherapy before hormonal therapy to hormonal therapy alone in the population of subjects with metastatic or high risk disease.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, 3) the availability of chemotherapy such as cabazitaxel that can improve survival in subjects with advanced disease and 4) that chemotherapy (docetaxel) given concomitant with hormone treatment has proven to prolong time to progression.
It is the investigators hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment.
This trial will determine whether any benefit is gained by adding chemotherapy before hormonal therapy to hormonal therapy alone in the population of subjects with metastatic or high risk disease. Two therapeutic approaches will be compared in this two-arm randomized clinical trial. The control Arm A provides hormonal therapy alone. The experimental Arm B involves treatment with hormone therapy + Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable or responding disease up to 10 cycles. For the schematic representation of study design please see Section 7.3.1.
Subjects with primary metastatic or N+ or high risk disease (PSA>100) will be eligible. The primary endpoint of the trial is overall survival.
Based on the yearly number of prostate cancer patients who are diagnosed with metastatic or high risk disease, approximately 1200 men per year (if +15% improvement)are potential candidates for this approach in the Scandinavian countries .
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Örebro, Швеция, 70185
- Рекрутинг
- University Hospital of Örebro
-
Контакт:
- Ove Andren, MD
- Электронная почта: ove.andren@orebroll.se
-
Главный следователь:
- Ove Andren, MD
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Histological or cytological confirmed prostate adenocarcinoma Metastatic PC (Prostate cancer) with measurable or evaluable disease or High risk PC (PSA > 100) or Node positive disease (N+)
- No prior treatment for prostate cancer (including bisfosfonate)
- Age above 18 years
- ECOG 0- 2
- Estimated survival > 3 months
- WBC 2000 / mm 3, neutrophils ≥1500 / mm 3, platelets 100,000 / mm 3
- Satisfactory liver function: bilirubin, transaminases ≤ 1.5 times the upper limit of normal.
- Satisfactory renal function. Serum creatinine <1.5 x ULN (150 mmol/l). If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance >60 mL/min are accepted in the study. https://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfr
- Patient information and signature of informed consent
Exclusion Criteria:
- Cardiovascular disease (severe symptomatic coronary artery disease, congenital heart failure, class 3 and 4 of the NYHA)
- Severe peripheral neuropathy
- Active infection or other serious underlying pathology that could prevent patients from receiving treatment
- History of cancer within 5 years before inclusion in the study other than basal cell or squamous cell skin cancer adequately treated
- Brain metastases, uncontrolled symptomatic or asymptomatic
- Patient participating in another clinical trial protocol with a molecule during this experimental study or treated four weeks prior to randomization.
- Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B)
- Systemic treatment with high dose steroids
- Any severe acute or chronic medical condition which would impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures.
- History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Arm A:
|
Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Другие имена:
|
|
Активный компаратор: Arm B:
-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
|
LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Overall survival
Временное ограничение: From date of randomization until date of death from any cause, assessed up to 7 years.
|
From date of randomization until date of death from any cause, assessed up to 7 years.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression free survival
Временное ограничение: From date of randomization until progression, assessed up to 3 years.
|
Ct and bonescan at three and six months and then at progession.
PSA assesments every three moths during the first year and then every six months until progression.
|
From date of randomization until progression, assessed up to 3 years.
|
|
PSA response
Временное ограничение: From date of randomization up to 7 years.
|
Assements every three months during the first year.
Then every six months until progression.
Then after progression every 12 months.
|
From date of randomization up to 7 years.
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Ove Andrén, Ass Prof., University hospital Örebro
- Главный следователь: Marie Hjelm-Eriksson, MD, Karolinska University Hospital
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования
- Урогенитальные новообразования
- Новообразования по локализации
- Генитальные новообразования, мужчины
- Заболевания предстательной железы
- Новообразования предстательной железы
- Физиологические эффекты лекарств
- Молекулярные механизмы фармакологического действия
- Противоопухолевые агенты
- Гормоны
- Гормоны, заменители гормонов и антагонисты гормонов
- Противоопухолевые агенты, гормональные
- Защитные агенты
- Эстрогены
- Микроэлементы
- Витамины
- Антиоксиданты
- Анаболические агенты
- Аскорбиновая кислота
- Андрогены
- Метилтестостерон
- Эстрогены, конъюгированные (USP)
Другие идентификационные номера исследования
- 2011-0030-78-10
- 2011-003078-10 (Номер EudraCT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .